Summit Therapeutics is trading 5.32% down at $16.90, despite broad U.S. market gains on September 21, 2026, with no confirmed company-specific catalyst for the decline.
- Latest identifiable company news remains the September 15 HARMONi trial update.
- The update reported consistent overall-survival results, rather than a negative development.
- Current evidence points to an unexplained, company-specific selloff rather than broader market weakness.